Impact on Healthcare
In developed countries, end-stage renal disease (ESRD) is a major cost driver for healthcare systems, with annual growth of dialysis programs ranging between 6% and 12% over the past two decades and continuing to grow, particularly in developing countries.
The most obvious societal effect of chronic kidney disease (CKD) is the enormous financial cost and loss of productivity associated with advanced kidney disease. For instance, many developed nations spend more than 2–3% of their annual healthcare budget to provide treatment for ESRD, while the population with ESRD represents approximately 0.02–0.03% of the total population1.
A strong argument to increasing PD use is therefore costs. For example, while the average costs in the US related to ESRD HD patient amount to USD 91’795 per year, the average cost for PD treatments was about 15% lower in 2017 (USD 78’159 per year)2.